Core Insights - The company reported a revenue of 2.995 billion yuan for the first half of 2025, representing a year-on-year growth of 6.21%, and a net profit attributable to shareholders of 241 million yuan, up 9.6% year-on-year [1] - In Q2 2025, the company achieved a revenue of 1.514 billion yuan, with a year-on-year increase of 3.29%, and a net profit of 133 million yuan, reflecting an 18.04% year-on-year growth and a 23.59% quarter-on-quarter increase [1] - The company has maintained a compound annual growth rate (CAGR) of 24.59% in revenue over the past 14 years, demonstrating resilience against changes in the international business environment [1] Business Performance - The core business of anti-aging additives generated a revenue of 2.358 billion yuan in the first half of 2025, with a year-on-year growth of 3.06% and a shipment volume of 65,500 tons, up 4.30% year-on-year [2] - The lubricating oil additives segment reported a revenue of 618 million yuan, marking an 18.49% year-on-year increase, with a shipment volume of 34,200 tons, up 18.27% year-on-year [2] - The life sciences division has transitioned its bio-block business from R&D to market development, achieving monthly sales exceeding one million yuan for key products [2] Strategic Initiatives - The company has initiated an overseas capacity expansion plan, establishing a wholly-owned subsidiary in Malaysia to invest up to 300 million USD in a research and production base for high-performance polymer materials and lubricating oil additives [1][2] - The company is actively participating in the formulation of Chinese standards for engine lubricants and collaborating with major international and domestic players in the lubricating oil additives sector [2] - The company is also focusing on cross-border mergers and acquisitions to integrate polyimide technology and establish dual R&D centers and production bases domestically and internationally [2] Financial Projections - The company is projected to achieve revenues of 6.113 billion yuan, 6.603 billion yuan, and 7.593 billion yuan for the years 2025, 2026, and 2027, respectively, with net profits of 495 million yuan, 505 million yuan, and 636 million yuan [3] - The expected earnings per share (EPS) for the same period are 2.16 yuan, 2.20 yuan, and 2.77 yuan, with corresponding price-to-earnings (PE) ratios of 15.6x, 15.3x, and 12.1x [3]

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 29.54 RMB [5][6]. Core Views - The company reported a steady performance in Q1 2025, achieving revenue of 1.5 billion RMB, with a quarter-on-quarter increase of 9% and a year-on-year increase of 4%. The net profit attributable to shareholders was 100 million RMB, showing a slight quarter-on-quarter increase of 0.7% but a year-on-year decrease of 4% [1]. - The company is expected to have growth potential due to the gradual ramp-up of new projects and the ongoing industrialization of electronic-grade PI and life sciences sectors [1]. - The company is expanding its market presence, particularly in the lubricant additive sector, with a focus on internationalization through the establishment of a research and production base in Malaysia [2]. - The life sciences segment has shown significant progress, with a pilot workshop for nucleic acid monomers and partnerships with nearly 90 clients, indicating a strong market transition from R&D to dual-track operations [3]. Summary by Sections Financial Performance - The company achieved a gross margin of 21.52% in Q1 2025, remaining stable compared to previous periods. The comprehensive expense ratio was 12%, with a slight increase attributed to higher R&D expenses [2]. - The forecast for net profit attributable to shareholders for 2025-2027 is 480 million, 530 million, and 580 million RMB, respectively, with year-on-year growth rates of 14%, 10%, and 10% [4]. Market Expansion - The company is actively exploring new markets, with a notable 15% increase in lubricant additive exports from Liaoning province in Q1 2025 [2]. - The establishment of a production base in Malaysia is expected to enhance the company's international competitiveness and risk resilience [2]. Business Development - The life sciences segment has made strides with the introduction of the phosphoramidite monomer into the supply chain of downstream clients, and the dNTP products have reached advanced domestic levels with over 70 client collaborations [3]. - The company has completed the acquisition of Yixing Chuangju and is set to supply flexible display leaders in bulk by 2025, indicating a robust growth trajectory in the polyimide sector [3].